Location:

Local - Boston Metro

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Study Identifies Agent That Can Reverse Resistance to Targeted Drug in Some Leukemia Cell Types

• Azacitidine reverses resistance to SL-401 in AML and BPDCN cell lines, researchers find • Results prompt clinical trial of SL-401 and azacitidine in AML and MDS patients

Science

Channels:

Data Analysis, Weather And Joint Pain, Medicare records

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 13-Dec-2017 6:30 PM EST

Medicine

Science

Channels:

Alzheimer's Disease, clinical trial, Clinical & Translational Research, Dementia

Clinical Trials on Alzheimer’s Disease: Shifting the Focus to Prevention

This past decade, Alzheimer’s science has undergone a paradigm shift toward the disease’s early, silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?

Medicine

Channels:

Hematologic Cancers, Leukaemia

Study Shows Combining Chemotherapy with Targeted Drug Boosts Response in Chronic Lymphocytic Leukemia

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

Medicine

Channels:

Multiple Myeloma, Hematologic Cancers

Sequencing Offers Clues to Progression Toward Multiple Myeloma

Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn’t show outward symptoms.

Medicine

Channels:

multiple myelmoma, Hematologic Cancers

Tracking How Multiple Myeloma Evolves by Sequencing DNA in the Blood

Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, eventually, deliver more effective treatments.

Medicine

Channels:

Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder

• Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis • Study shows one of multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.

Medicine

Channels:

IL2, Cancer

Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.

Science

Channels:

multiple myelmoma, Cancer, Hematologic Cancers

Study Explores Use of Checkpoint Inhibitors After Relapse From Donor Stem Cell Transplant for Hematologic Cancers

Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial in these patients of one such agent – nivolumab – indicate that along with signs of effectiveness, it also produced significant side effects at the dose initially studied. The findings indicate a need for further clinical trials in this group before being considered for off-label use with these patients, Dana-Farber Cancer Institute investigators report.

Medicine

Science

Channels:

Oxytocin, Hippocampus, Harvard Medical School

How a Seahorse-Shaped Brain Structure May Help Us Recognize Others

image002.gif

Study in mice reveals a brain circuit that regulates social memory formation and recognition. Results shed light on brain’s ability to reconcile conflicting social stimuli, and shed light on anomalies in social behavior seen in neurodevelopmental, neurologic and psychiatric disorders







Chat now!